bims-miptne Biomed News
on Mitochondrial permeability transition pore-dependent necrosis
Issue of 2026–11–08
twelve papers selected by
Oluwatobi Samuel Adegbite, University of Liverpool



  1. Mol Neurobiol. 2026 Nov 04. pii: 1011. [Epub ahead of print]63(1):
      Alzheimer's disease (AD) is a neurodegenerative disorder defined by accumulation of amyloid-β (Aβ), tau pathology, synaptic failure and neuronal loss. Increasing evidence suggests that perturbation of mitochondrial Ca2⁺ homeostasis is something important in AD pathogenesis. The Mitochondrial Calcium Uniporter (MCU) complex brings the major route for Ca2⁺ uptake into mitochondria, linking cellular Ca2⁺ signalling to Adenosine triphosphate (ATP) production and neuronal function. Factors related to AD, including Aβ oligomers, presenilin mutations, pathological tau and apolipoprotein E ε4 (APOE4) promote enhanced transfer of Ca2⁺ from the endoplasmic reticulum (ER) to mitochondria, resulting in mitochondrial Ca2⁺ overload. This initiates toxic pathways including neuroinflammation, production of reactive oxygen species (ROS), mitochondrial permeability transition pore opening (mPTP), ATP depletion and neuronal cell death. Recent studies have identified miR-25 as a regulator of MCU expression in experimental systems, while other AD-associated miRNAs, including miR-132, miR-124, and miR-155, are implicated in synaptic dysfunction, mitochondrial stress, and neuroinflammatory signalling. Their direct involvement in MCU regulation in Alzheimer's disease remains to be established. Here we review the composition and function of the MCU complex and its contribution to AD pathology, including the outstanding question of whether increased or decreased MCU activity occurs at different stages of disease development. Treatment strategies that target mitochondrial Ca2⁺ homeostasis, including the use of MCU blockers, mitochondrial Na⁺/Ca2⁺ exchanger (NCLX) activators, therapies that target ER-mitochondria contacts, and microRNA-based therapies will also be discussed. So, the MCU complex shows considerable promise as a potential therapeutic target and disease biomarker.
    Keywords:  Alzheimer’s disease; MiRNA; Mitochondrial calcium uniporter; Neuroinflammation; Oxidative stress; Synaptic dysfunction
    DOI:  https://doi.org/10.1007/s12035-026-06298-6
  2. Cell Rep. 2026 Nov 06. pii: S2211-1247(26)01346-X. [Epub ahead of print]45(11): 118267
      Multiple myeloma is a plasma cell malignancy that develops within the bone marrow. The bone marrow metabolome is altered in myeloma, with implications for malignant cell growth. Here, the impact of elevated bone marrow levels of the tricarboxylic acid (TCA) cycle metabolite, succinate, was interrogated. Succinate was found to promote proliferation of several myeloma cell lines. This was linked to its uptake and oxidation in the TCA cycle, as indicated by increased ATP-coupled mitochondrial respiration and incorporation of succinate-derived carbons into downstream TCA cycle intermediates, which also occurs in primary myeloma cells. Succinate-driven proliferation was dependent upon mitochondrial oxidative phosphorylation and abrogated by ATP synthase inhibition. Furthermore, interrogation of large-scale transcriptomic data identified that elevated expression of a mitochondrial succinate transporter associates with accelerated disease progression in myeloma, indicating this mechanism may promote plasma cell growth in vivo and highlighting a target for therapeutic intervention.
    Keywords:  CP: cancer; CP: metabolism; anti-tumour immunity; cancer; cancer metabolism; immunometabolism; metabolism; metabolites; mitochondria; multiple myeloma; succinate
    DOI:  https://doi.org/10.1016/j.celrep.2026.118267
  3. Mol Cell Proteomics. 2026 Nov 03. pii: S1535-9476(26)00197-0. [Epub ahead of print] 101701
      Brain aging is a spatially heterogeneous and multi-layered process, yet how protein abundance and post-translational modifications (PTMs) are coordinated across brain regions and over time remains incompletely understood. Here, we present a brain-region-resolved, multi-layer proteomics atlas of mouse brain aging, integrating the proteome, phosphoproteome, acetylome, and ubiquitinome across 11 anatomical regions and five time points spanning from young adulthood to senescence. Using dia-PASEF with PTM-optimized acquisition, we quantified 11,460 proteins with 29,225 phosphorylation sites, 5345 acetylation sites, and 5197 ubiquitination sites across 628 injections, enabling systematic analysis of age-associated molecular trajectories. We find that aging patterns are highly region-specific at both the protein and PTM levels, and the pons emerges as a region with marked phosphorylation-level alterations in aging-related signaling pathways. Notably, we uncover a proteostasis-centered regulatory axis in the aging hippocampus, where reduced ubiquitination and increased acetylation converge on Tau, potentially impairing its degradation. Using a telomerase-deficient mouse model (Tert KO), we show that telomere dysfunction perturbs aging-associated molecular trajectories and induces a divergent proteostasis and stress-response state distinct from physiological brain aging. Together, our study provides a spatiotemporal multi-layer proteomics resource of brain aging and reveals a proteostasis-centered landscape of post-translational remodeling associated with region-specific vulnerability and Tau dysregulation.
    DOI:  https://doi.org/10.1016/j.mcpro.2026.101701
  4. Nat Commun. 2026 Oct 07. pii: 11402. [Epub ahead of print]17(1):
      Deoxycytidine (dC) analogues are widely used to treat solid tumours and blood cancers. However, their clinical efficacy is often limited by resistance mediated by cytidine deaminase (CDA), which converts these drugs into inactive metabolites. Existing CDA inhibitors have limited efficacy and off-target effects, highlighting the need for alternative approaches. Here, we show the development of a CDA biodegrader, an intracellular anti-CDA VHH fused to the SPOP E3 ubiquitin ligase, enabling specific CDA degradation. It effectively depletes CDA in pancreatic, lung, and acute myeloid leukaemia cancer cell lines, increasing sensitivity to dC analogues in vitro. Combined with gemcitabine, the CDA biodegrader inhibits pancreatic and lung tumour growth in vivo. Importantly, mRNA encoding the biodegrader delivered using virus-like particles achieves efficient sensitisation to gemcitabine in vitro and in vivo. This proof-of-concept study establishes targeted CDA degradation as a feasible strategy to enhance the therapeutic efficacy of dC analogues.
    DOI:  https://doi.org/10.1038/s41467-026-78315-0
  5. Nat Commun. 2026 Oct 07. pii: 11424. [Epub ahead of print]17(1):
      Mitochondria import hundreds of proteins into the matrix and the inner membrane (IM). The translocase of the IM of mitochondria (TIM23 complex) sorts these proteins using topogenic signals in their structure and directs them into the matrix or inserts them into the IM. How these signals are deciphered is unknown. Here we show that Tim17, the protein-conducting subunit of the TIM23 complex, contains a highly conserved selectivity filter for incoming proteins. Using a fluorescence-based sorting reporter, we identified the mitochondrial oxidoreductase Dmo2 (akin to DMAC1 in humans) as factor for intramitochondrial protein sorting. Molecular dynamics simulations show that a Dmo2-dependent disulfide bond into Tim17 constitutes a negatively charged selectivity filter at the vestibule of the TIM23 complex that arrests membrane proteins and facilitates the lateral insertion. Our work provides a molecular rationale as to how the TIM23 translocase differentiates between soluble and membrane proteins.
    DOI:  https://doi.org/10.1038/s41467-026-77990-3
  6. Proc Natl Acad Sci U S A. 2026 Nov 10. 123(45): e2602240123
      System-level mapping of kinase inhibitors' polypharmacology can uncover opportunities for drug repurposing and identify starting points for medicinal chemistry campaigns aimed at novel targets. Here, we describe a large-scale profiling of 257 kinase inhibitors that revealed domains of promiscuity, a broad region of uninhibited targets and discrete pockets of selectivity. Focusing on a subcluster enriched for AGC group kinases and using the AKT inhibitor AT-7867 (an antiproliferative agent) as a starting point, we employed scaffold hopping and property-based optimization to discover NCGC-6782, a LATS1/2 inhibitor with robust proproliferative activity. In biochemical and cell-based assays, NCGC-6782 inhibited LATS1/2 activity, reduced YAP phosphorylation, and promoted rapid YAP nuclear translocation and transactivation of YAP-target genes. Kinome-wide profilings demonstrated good in vitro selectivity and exquisite chemoproteomic and kinetic selectivity. In vivo, NCGC-6782 exhibited favorable pharmacokinetic (PK) profiles following intraperitoneal (IP), intravenous (IV), or oral (PO) dosing, leading to rapid inhibition of YAP-phosphorylation in murine liver samples. Transcriptomics and proteomics following NCGC-6782 revealed upregulation of YAP-dependent genes (4 h) followed by activation of cell cycle programs (24 h). Consistently, NCGC-6782 accelerated proliferative regeneration in both cell-based and in vivo wound healing models of full-thickness excisional skin injury, significantly shortening wound-closure time without evidence of systemic toxicity. Altogether, we describe an optimized, potent, and selective LATS1/2 kinase inhibitor with desirable drug-like properties and broad potential for regenerative medicine applications following acute injury of nonproliferative, postmitotic tissues.
    Keywords:  Hippo signaling; LATS1; LATS2; NCGC-6782; regenerative medicine
    DOI:  https://doi.org/10.1073/pnas.2602240123
  7. J Biol Chem. 2026 Nov 02. pii: S0021-9258(26)02582-2. [Epub ahead of print] 113710
      Ribonucleotide reductase (RNR) is the rate-limiting enzyme in deoxyribonucleotide synthesis and is therefore essential for DNA replication, repair, and cell-cycle progression. Because cancer cells rely heavily on nucleotide production to sustain proliferation and genome maintenance, RNR has long been an important therapeutic target. However, while several RNR inhibitors are clinically approved, their utility can be impacted by dose-limiting toxicities, poor pharmacokinetic and pharmacodynamic properties, and diverse mechanisms of therapeutic resistance. In this review, we examine emerging mechanisms that regulate RNR in cancer beyond canonical cell-cycle and DNA-damage pathways that could serve as additional targets for blocking RNR. We discuss subunit-specific transcriptional and epigenetic programs, post-translational modifications, protein-protein interactions, and signaling crosstalk that control RRM1, RRM2, and RRM2B expression and activity. We further highlight non-canonical functions of RNR subunits in PI3K/AKT, MAPK/ERK, immune, epithelial-to-mesenchymal transition (EMT), antioxidant, and ferroptosis pathways, emphasizing how these activities may contribute to tumor progression and drug resistance. We summarize mechanisms underlying resistance to conventional RNR inhibitors, including altered drug transport and metabolism, RNR overexpression, and acquisition of stem-like and EMT phenotypes with an emphasis on approaches to overcome these limitations. Lastly, we provide an in-depth summary of preclinical RNR inhibitors, highlighting how they compare to FDA-approved RNR inhibitors and their progression in clinical trials. Collectively, these advances underscore the role of RNR in tumorigenesis and identify opportunities to develop more selective and effective RNR-targeted therapies.
    DOI:  https://doi.org/10.1016/j.jbc.2026.113710
  8. Mol Cell. 2026 Nov 03. pii: S1097-2765(26)00713-6. [Epub ahead of print]
      Calcium release in host cells is essential for viral infection and survival, and mutations disrupting calcium homeostasis are associated with chronic viral infections or autoimmune diseases in patients, yet the biological significance of calcium (Ca2+) signaling on stimulator of interferon genes (STING) activation remains unclear. Here, we show that cytosolic Ca2+ is sensed by host cells as an immediate-early danger signal. Viral infection-activated Rho GTPases and phospholipase C-β (PLCβ) induce ITPR-mediated endoplasmic reticulum (ER) Ca2+ release, while STING translocation induces TRPV2-mediated ER Ca2+ release, both leading to store-operated Ca2+ entry (SOCE) through ORAI channels. Ca2+ influx activates calmodulin (CaM)-dependent protein kinases CaMKK and CaMK1D. Activated CaMK1D phosphorylates STING, allowing for TBK1 trans-autophosphorylation. Inhibiting Ca2+ signaling or mutating CaMK1D-phosphorylating STING sites impairs STING activation. Consistently, Ca2+ signaling is important for the host defense against DNA viruses in mice. These results support a two-signal mode for STING activation in which the Ca2+-CaM-CaMKK-Ca2+/calmodulin-dependent protein kinase (CaMK) cascade is indispensable.
    Keywords:  CAMK; Ca(2+); ITPR; ORAI channels; Rho GTPase; STIM; STING; TRPV2; phospholipase C; viral infection
    DOI:  https://doi.org/10.1016/j.molcel.2026.10.008
  9. Proc Natl Acad Sci U S A. 2026 Nov 10. 123(45): e2602326123
      Talin is a mechanosensitive scaffold that couples integrins to the actin cytoskeleton and coordinates signaling at integrin adhesion complexes. A second integrin-binding site (IBS2) has been proposed within the R11-R12 region of the talin rod, although the molecular basis of this interaction has remained unclear. Here, we show that talin R11 contains a cryptic aggregation-prone region (APR) embedded within Helix50. Mechanical unfolding of R11 exposes this motif, enabling high-affinity talin-talin interactions and force-dependent self-association. The isolated APR forms amyloid-like fibers in vitro, and APR-disrupting gatekeeper mutations suppress fiber formation, talin self-association, and cellular recruitment. We therefore designate this motif Aggregation-Prone Region 1 (APR1). Mitochondrial-targeting experiments demonstrate that APR1-dependent recruitment occurs in cells independently of focal adhesions and integrins. APR1 overlaps the vinculin-binding site in Helix50, and vinculin disrupts preexisting talin assemblies, revealing a mechano-chaperone function for vinculin. Disruption of APR1-mediated self-association does not impair adhesion formation but instead generates larger, more talin-rich adhesions with altered assembly dynamics and signaling properties, indicating a role for APR1 in regulating adhesion remodeling. Together, these findings identify force-dependent talin self-association as a mechanism in mechanotransduction and suggest that the region previously designated IBS2 functions primarily as an aggregation-prone regulatory element.
    Keywords:  cell adhesion; integrin; mechanobiology
    DOI:  https://doi.org/10.1073/pnas.2602326123
  10. Nat Commun. 2026 Oct 09. pii: 11476. [Epub ahead of print]17(1):
      Pediatric mitochondrial disease (PMD) is challenging due to its genetic heterogeneity, diagnostic difficulty, and unpredictable trajectories. Current biomarkers lack sensitivity to diagnose PMD or predict its severe course. Here, we show a multi-omics framework with longitudinal monitoring to resolve these challenges. We identify metabolic and transcriptomic dysregulation in PMD, deriving a robust 7-feature multi-omics diagnostic panel (6 metabolites, 1 transcript). In an independent validation cohort, this panel achieved superior diagnostic accuracy (AUC = 0.96) compared to conventional biomarkers. Beyond diagnosis, we addressed the need for patient stratification. Unsupervised proteomic clustering revealed two subtypes (Cluster I and II) that diverged over time; Cluster II patients had downregulation of cytoskeletal and immune pathways and worse clinical outcomes at 12 months. We leveraged these insights to develop a 12-transcript prognostic signature that predicts clinical prognostication with high accuracy (AUC = 0.85). This study establishes a molecular framework for PMD, offering validated tools for precision diagnosis and prognostic stratification.
    DOI:  https://doi.org/10.1038/s41467-026-78387-y
  11. Nature. 2026 Nov 04.
      Ribosomal frameshifting, an uncommon translational recoding event, is best known for its regulatory roles in viral gene expression1,2, whereas its physiological relevance in mammals remains poorly understood. Here we show that specific codon pairs trigger efficient -1 frameshifting preferentially in cancer cells. Mechanistically, this recoding arises from ribosomal pausing associated with tRNA and amino acid availability, and is amplified by impaired ribosome quality control and sustained phosphorylation of ribosomal protein S6. We found that this codon-pair-specific frameshifting represents an intrinsic state of translational dysregulation, which is prevalent across cancer cells and reshapes protein synthesis. Taking advantage of this frameshifting-permissive state in cancer cells, we engineered a frameshifting-activated synthetic therapeutic circuit (FAST) that conditionally expresses the pyroptotic effector gasdermin D. FAST is activated across diverse cancer cell types, inducing potent and selective pyroptosis, while sparing normal tissues from detectable toxicity. As a proof of concept, systemic AAV9-mediated delivery of FAST in mouse models of colorectal and pancreatic cancer elicited pronounced tumour regression, robust immune activation and synergistic effects with immune checkpoint blockade. Collectively, these findings reveal codon-pair-dependent ribosomal frameshifting as a feature of translational dysregulation in cancer cells and establish translation-coupled gene circuits as a strategy for cancer-selective therapy.
    DOI:  https://doi.org/10.1038/s41586-026-11200-4
  12. Nat Commun. 2026 Oct 07. pii: 11429. [Epub ahead of print]17(1):
      Proteolysis-targeting chimeras (PROTACs) represent a transformative therapeutic modality, yet the viability of covalent PROTACs remains debated, as irreversible binding seemingly contradicts the catalytic mechanism of action. Here, we develop and characterize PSIRC3, a potent covalent PROTAC for Bruton's tyrosine kinase (BTK). PSIRC3 induces selective BTK degradation with a sub-nanomolar DC50 of 0.75 nM and a Dmax of 85%, while its non-covalent counterpart is inactive. Such activity requires covalent bond formation with Cys481, as efficacy is abolished against the C481S BTK mutant. PSIRC3 achieves maximum BTK degradation within 30 min, a kinetic profile linked to rapid cell permeation and efficient ternary complex formation. In vivo, a single administration of PSIRC3 leads to substantial BTK degradation in both PBMCs ( > 80%) and splenocytes ( > 50%). Computational modeling, parameterized with our experimental data, reveals that degradation efficacy is governed by a balance between E3 ligase and target affinities: excessively high E3 affinity is detrimental by inducing a hook effect, while higher target affinity is generally beneficial. Our findings provide strong evidence that covalent engagement can drive potent and selective protein degradation, challenging the notion that catalytic turnover is indispensable for PROTAC efficacy, and open avenues for targeting intractable proteins.
    DOI:  https://doi.org/10.1038/s41467-026-78239-9